These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28749904)

  • 1. Use of genetic markers in multiple myeloma.
    Fonseca R
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):446-448. PubMed ID: 28749904
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward personalized treatment in multiple myeloma based on molecular characteristics.
    Pawlyn C; Davies FE
    Blood; 2019 Feb; 133(7):660-675. PubMed ID: 30587529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta).
    Tassone P; Tagliaferri P
    Curr Cancer Drug Targets; 2012 Sep; 12(7):741-2. PubMed ID: 22934915
    [No Abstract]   [Full Text] [Related]  

  • 4. The genetic architecture of multiple myeloma.
    Morgan GJ; Walker BA; Davies FE
    Nat Rev Cancer; 2012 Apr; 12(5):335-48. PubMed ID: 22495321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.
    Soliman AM; Das S; Teoh SL
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Towards precision medicine in myeloma: new evidence and challenges].
    González-Calle V; Fonseca R
    Medicina (B Aires); 2017; 77(3):222-226. PubMed ID: 28643680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length.
    Boyle EM; Williams L; Blaney P; Ashby C; Bauer M; Walker BA; Ghamlouch H; Choi J; Perrial E; Wang Y; Caro J; Stoeckle JH; Arbini A; Kaminetzky D; Braunstein M; Bruno B; Razzo B; Diamond B; Maclachlan K; Maura F; Landgren O; Litke R; Fegan CD; Keats J; Auclair D; Davies FE; Morgan GJ
    Leukemia; 2022 Jan; 36(1):221-224. PubMed ID: 34148053
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
    Tacchetti P; Pezzi A; Zamagni E; Pantani L; Rocchi S; Zannetti BA; Mancuso K; Rizzello I; Cavo M
    Haematologica; 2017 Mar; 102(3):e104-e107. PubMed ID: 27909220
    [No Abstract]   [Full Text] [Related]  

  • 9. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells.
    Cohen Y; Gutwein O; Garach-Jehoshua O; Bar-Haim A; Kornberg A
    Hematology; 2013 Nov; 18(6):348-51. PubMed ID: 23510526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloma researchers gain genome, new targets, and new concerns.
    Brower V
    J Natl Cancer Inst; 2011 Jul; 103(14):1082-5. PubMed ID: 21737696
    [No Abstract]   [Full Text] [Related]  

  • 11. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.
    Chim CS; Liang R; Fung TK; Choi CL; Kwong YL
    J Clin Pathol; 2007 Jun; 60(6):664-9. PubMed ID: 17557868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influencing the Wnt signaling pathway in multiple myeloma.
    Kim Y; Reifenberger G; Lu D; Endo T; Carson DA; Gast SM; Meschenmoser K; Nowak M; Schmidt-Wolf IG
    Anticancer Res; 2011 Feb; 31(2):725-30. PubMed ID: 21378363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
    Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
    Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
    Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
    Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-κB dysregulation in multiple myeloma.
    Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
    Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of circulating miRNAs in multiple myeloma.
    Zhang J; Xiao X; Liu J
    Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards Stratified Medicine in Plasma Cell Myeloma.
    Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of WT1 gene in multiple myeloma patients at diagnosis: is WT1 gene expression a useful marker in multiple myeloma?
    Saatci C; Caglayan AO; Kocyigit I; Akalin H; Kaynar LG; Altuntas F; Eser B; Demir M; Cetin M; Ozkul Y
    Hematology; 2010 Feb; 15(1):39-42. PubMed ID: 20132661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting MEK in MAPK pathway-activated myeloma.
    Heuck CJ; Jethava Y; Khan R; van Rhee F; Zangari M; Chavan S; Robbins K; Miller SE; Matin A; Mohan M; Ali SM; Stephens PJ; Ross JS; Miller VA; Davies F; Barlogie B; Morgan G
    Leukemia; 2016 Apr; 30(4):976-80. PubMed ID: 26228812
    [No Abstract]   [Full Text] [Related]  

  • 20. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.